Swiss food giant Nestle beats Danone for the control of Pfizer’s infant nutrition business. This $11.9 billion cash deal allows Nestle to expand its footprint in the global baby food market, while Pfizer could now focus on its core drug-making business. The baby infant nutrition business has been a growing segment in the healthy food category, with the emerging markets contributing most of the growth.
Read more on Dealbook.
There are no comments yet. Add your comment to start the conversation.